NeuroBo Pharmaceuticals Dirección

Dirección controles de criterios 1/4

El CEO de NeuroBo Pharmaceuticals es Hyung-Heon Kim , nombrado en Aug 2023, tiene una permanencia de 1.25 años. compensación anual total es $1.01M, compuesta por 17.2% salario y 82.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.32% de las acciones de la empresa, por valor de $66.79K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 3.3 años, respectivamente.

Información clave

Hyung-Heon Kim

Chief Executive Officer (CEO)

US$1.0m

Compensación total

Porcentaje del salario del CEO	17.2%
Permanencia del CEO	1.3yrs
Participación del CEO	0.3%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Oct 03

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Sep 29

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

Sep 14

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

Sep 12

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

Nov 25

NeuroBo on track to post a record gain after announcing a special meeting

Jun 14

NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition

Jan 06

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

Dec 21

NeuroBo Pharmaceuticals EPS misses by $0.02

Nov 13

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Hyung-Heon Kim en comparación con los beneficios de NeuroBo Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	US$1m	US$174k	-US$12m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$61k	n/a	-US$14m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$14m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$29k	n/a	-US$15m

Compensación vs. Mercado: La compensación total de Hyung-Heon($USD1.01M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD646.00K).

Compensación vs. Ingresos: La compensación de Hyung-Heon ha aumentado mientras la empresa no es rentable.

CEO

Hyung-Heon Kim (49 yo)

1.3yrs

Permanencia

US$1,012,073

Compensación

Mr. Hyung-Heon Kim had been Independent Director of NeuroBo Pharmaceuticals, Inc. since July 09, 2021 until August 11, 2023 and serves as its Chief Executive Officer, President of NeuroBo Pharmaceuticals,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Hyung-Heon Kim	CEO, President & Director	1.3yrs	US$1.01m	0.32% $ 66.8k
Marshall Woodworth	Chief Financial Officer	1.1yrs	US$154.50k	sin datos
Mi-Kyung Kim	Chief Scientific Officer	1.3yrs	sin datos	sin datos
Robert Homolka	Senior Vice President of Clinical Operations	1.3yrs	sin datos	sin datos

1.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de NRBO no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hyung-Heon Kim	CEO, President & Director	3.3yrs	US$1.01m	0.32% $ 66.8k
D. Strickland	Independent Director	2.8yrs	US$110.71k	0.11% $ 23.6k
Andrew Koven	Independent Chairman of the Board	3.3yrs	US$140.84k	0.11% $ 23.6k
Michael Salsbury	Independent Director	4.9yrs	US$102.36k	0.11% $ 23.6k
Roy Freeman	Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Mark Glickman	Independent Director	1.5yrs	US$50.47k	0.045% $ 9.5k
Caroline Apovian	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jason Groves	Independent Director	4.9yrs	US$100.35k	0.11% $ 23.6k
James Tursi	Independent Director	less than a year	US$21.93k	0.029% $ 5.9k
Leigh Perreault	Member of Scientific Advisory Board	no data	sin datos	sin datos

3.3yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NRBO se considera experimentada (3.3 años de antigüedad promedio).

NeuroBo Pharmaceuticals Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee

NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Acting Chief Financial Officer

NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon (Irene) Kim from the Board of Directors

NeuroBo Pharmaceuticals, Inc. Announces Executive Changes

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2023

Recent updates

New major risk - Financial position

NeuroBo Pharmaceuticals, Inc. Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Neurobo Pharmaceuticals Announces Positive Top-Line Data from the Sad Part 1 of Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals, Inc. Doses First Patient in the MAD Part 2 of its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.000001 million.

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment

Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee

NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Acting Chief Financial Officer

NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon (Irene) Kim from the Board of Directors

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of Nash

NeuroBo Pharmaceuticals, Inc. Announces Executive Changes

NeuroBo Pharmaceuticals Receives 180-Day Extension to February 5, 2024 from Nasdaq to Regain Compliance with the Minimum Bid Price Requirement

Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2023

Neurobo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to Its Board of Directors

NeuroBo Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

NeuroBo Pharmaceuticals, Inc. Appoints Joseph Hooker as President

NeuroBo Pharmaceuticals, Inc. announced that it has received $15 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals Compliant with All Applicable Nasdaq Listing Criteria

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $37 million in funding from Dong-A ST Co., Ltd.

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Neurobo Pharmaceuticals, Inc. Appoints Matthew Bardin as Senior Vice President Operations

High number of new and inexperienced directors

NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

No longer forecast to breakeven

Independent Director Jeong Gyun Oh has left the company

No longer forecast to breakeven

Price target decreased to US$16.00

NeuroBo Pharmaceuticals, Inc.(NasdaqCM:NRBO) dropped from Russell 3000E Index

NeuroBo on track to post a record gain after announcing a special meeting

NeuroBo Pharmaceuticals, Inc. announced delayed annual 10-K filing

NeuroBo Pharmaceuticals, Inc. Announces Board Changes

New 90-day low: US$4.68

NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding

Neurobo Pharmaceuticals, Inc. Announces Executive Changes

Neurobo Pharmaceuticals, Inc. Appoints Akash Bakshi as Class II Director to the Board and Chief Operating Officer and Senior Vice President

New 90-day high: US$6.68

NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

NeuroBo Pharmaceuticals EPS misses by $0.02

New 90-day low: US$5.24

New 90-day low - US$5.80

New 90-day low - US$6.16

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad